| Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. | Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma.
Fischietti M, Eckerdt F, Blyth GT, Arslan AD, Mati WM, Oku CV, Perez RE, Lee-Chang C, Kosciuczuk EM, Saleiro D, Beauchamp EM, Lesniak MS, Verzella D, Sun L, Fish EN, Yang GY, Qiang W, Platanias LC., Free PMC Article | 08/27/2024 |
| SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer. | SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer.
Xu QP, Deng K, Zhang Z, Shang H., Free PMC Article | 03/1/2023 |
| Schlafen 5 suppresses human immunodeficiency virus type 1 transcription by commandeering cellular epigenetic machinery. | Schlafen 5 suppresses human immunodeficiency virus type 1 transcription by commandeering cellular epigenetic machinery.
Ding J, Wang S, Wang Z, Chen S, Zhao J, Solomon M, Liu Z, Guo F, Ma L, Wen J, Li X, Liang C, Cen S., Free PMC Article | 08/27/2022 |
| SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. | SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.
Martinez RS, Salji MJ, Rushworth L, Ntala C, Rodriguez Blanco G, Hedley A, Clark W, Peixoto P, Hervouet E, Renaude E, Kung SHY, Galbraith LCA, Nixon C, Lilla S, MacKay GM, Fazli L, Gaughan L, Sumpton D, Gleave ME, Zanivan S, Blomme A, Leung HY. | 12/18/2021 |
| Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription. | Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription.
Kim ET, Dybas JM, Kulej K, Reyes ED, Price AM, Akhtar LN, Orr A, Garcia BA, Boutell C, Weitzman MD., Free PMC Article | 04/24/2021 |
| Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription. | Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription.
Wan G, Zhu J, Gu X, Yang Y, Liu Y, Wang Z, Zhao Y, Wu H, Huang G, Lu C., Free PMC Article | 02/27/2021 |
| This is the first study to report that SLFN5 inhibits cancer migration and invasiveness in several common cancer cell lines by repressing MT1-MMP expression via the AKT/GSK-3beta/beta-catenin signalling pathway, suggesting that SLFN5 plays wide inhibitory roles in various cancers. | SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3β/β-catenin pathway.
Wan G, Liu Y, Zhu J, Guo L, Li C, Yang Y, Gu X, Deng LL, Lu C. | 08/12/2020 |
| Study results demonstrated that overexpression of SLFN5 promoted the morphology transformation of lung cancer cell line A549 from epithelial to mesenchymal, as well as migration and invasion. However, knockdown of SLFN5 resulted in the opposite results. Results suggest that SLFN5 may act as a synergist in lung cancer cell tumorigenesis and progression through beta-catenin/Snail/E-cadherin pathway. | Overexpression of SLFN5 induced the epithelial-mesenchymal transition in human lung cancer cell line A549 through β-catenin/Snail/E-cadherin pathway.
Guo L, Liu Z, Tang X. | 03/7/2020 |
| Type-I IFN treatment triggers the interaction of STAT1 with SLFN5, and the resulting complex negatively controls STAT1-mediated gene transcription via interferon stimulated response elements | Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma.
Arslan AD, Sassano A, Saleiro D, Lisowski P, Kosciuczuk EM, Fischietti M, Eckerdt F, Fish EN, Platanias LC., Free PMC Article | 11/4/2017 |
| In this study population, elevated SLFN5 protein expression in patients with intestinal metaplasia correlated with progression to gastric cancer | SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer.
Companioni Nápoles O, Tsao AC, Sanz-Anquela JM, Sala N, Bonet C, Pardo ML, Ding L, Simo O, Saqui-Salces M, Blanco VP, Gonzalez CA, Merchant JL., Free PMC Article | 09/23/2017 |
| SLFN5 exhibits key roles in controlling motility and invasiveness of renal cell carcinoma cells by negatively controlling expression of MMP-1, MMP-13, and several other genes involved in the control of malignant cell motility. | Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.
Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC., Free PMC Article | 10/3/2015 |
| SLFN5 knockdown also resulted in increased invasion in three-dimensional collagen, suggesting a dual role for SLFN5 in the regulation of invasion and anchorage-independent growth of melanoma cells. | Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells.
Katsoulidis E, Mavrommatis E, Woodard J, Shields MA, Sassano A, Carayol N, Sawicki KT, Munshi HG, Platanias LC., Free PMC Article | 01/15/2011 |